Skip to the content
AESTHETIC NEWSAESTHETIC NEWS
Daily Lifestyle, Fashion and Health News
Monday, March 20th, 2023
  • Home
  • Lifestyle
  • Beauty & Style
  • Literature
  • Fashion
  • Health
  • Contact

Impact Report: Colossal Sets New Goal After Raising Over $9.6M in 2022

March 17, 2023

4 Questions Spouses Should Ask Each Other Before Retirement

March 16, 2023

The Shocking Number of Gen Z’ers That Don’t Know Their Credit Score

March 16, 2023

The Biggest Hidden Costs of Divorce in 2023

March 16, 2023

Millennials Are Using Credit Cards for Their Emergency Funds, Which is Not Great

March 16, 2023

Sustainalytics Upgrades INNIO Group’s ESG Risk Rating From Low to Negligible Risk, Ranking INNIO Number 1 Worldwide Among Industry Peers

March 16, 2023

Baxter of California Celebrates Men of Culture With New Series Launch

March 16, 2023

Megafans Releases New NFT Collection for Esports Gamers and Collectors

March 15, 2023

OurFamilyWizard Unveils New Branding for Its Premium Co-Parenting Tools

March 15, 2023
Breaking News
Common Health Launches Southeast Asia’s First E-Commerce Platform for Chronic Diseases San Diego-Based Shoreline Recovery Center Addresses the Opioid Epidemic Among Young Adult Males With Education, Treatment and Comprehensive Programming Impact Report: Colossal Sets New Goal After Raising Over $9.6M in 2022 ZEUS Scientific Introduces the SP30 IFA Slide Processor for dIFine as Part of the dIFine 30 System ZEUS Scientific Introduces the SP30 IFA Slide Processor for dIFine as Part of the dIFine 30 System
  • Home
  • Health News
  • Surging COVID-19 hospitalizations strain U.S. health care system
Health News

Surging COVID-19 hospitalizations strain U.S. health care system

Editor
April 20, 2022



The Biden administration says Americans will be able to request free rapid COVID-19 tests starting next week. CBS News national …

Originally published at https://www.youtube.com/watch?v=AQ6A3yETtwM

More Stories

Common Health Launches Southeast Asia’s First E-Commerce Platform for Chronic Diseases

New Service Helps Save Money, Improve Health for Population of 151 Million

Common Health Launches Southeast Asia’s First E-Commerce Platform for Chronic Diseases


PROVIDENCE, R.I., March 19, 2023 (Newswire.com)
–
Common Health Inc., an American startup company working in Southeast Asia, announced today the launch of a new e-commerce platform dedicated to the region’s 151 million people with diabetes and hypertension. The service makes quality medicines more accessible and affordable, and provides advice and support to help customers live longer, healthier lives. Common Health is now available in Myanmar and can be accessed through www.commonhealth.com.mm, Facebook, Viber, and a telephone hotline.

Chronic diseases are a serious challenge in the region, where 99 million people are diabetic or pre-diabetic and 116 million people have hypertension, including many with both conditions. Due to the high costs for care and the complexities of living with these diseases, most people struggle to maintain their treatment. For example, only 12% of people in Southeast Asia with hypertension have their condition under control.

Common Health addresses this by making products and services for people with chronic diseases more affordable, accessible, and convenient, starting with essential medications. Every customer using the company’s platform has access to:

  • Low prices that deliver savings on every order, made possible by relationships with pharmacies, distributors, and manufacturers,
  • Convenient home delivery by a dedicated team trained on the safe handling of health products, including “cold-chain” items,
  • A wide range of medications for diabetes, hypertension, and hyperlipidemia, including Myanmar’s largest selection of oral diabetes drugs and insulins,
  • A world-class quality guarantee ensuring that products are authentic, legally imported, and in excellent condition, and
  • Free telemedicine support, including a family medicine doctor matched to each household and a 24-hour on-call service for urgent issues.

The company has piloted its chronic disease e-commerce platform in the cities of Yangon and Bago, and the response from customers like Daw Cho Cho Thein has been enthusiastic. “We save 25,000 kyats [~US$ 12] per family member on medication costs by ordering through Common Health,” said Thein, who cares for two parents with type 2 diabetes. “We do not need to worry about the expiration date on the medicines. And whenever we have questions, we call our family medicine doctor.”

Common Health was founded in 2019 by Matthew Guilford, who previously scaled telemedicine and health insurance to five million people in Bangladesh. The company began operations in Myanmar in 2021, supporting primary care, medicine delivery, and hospital access for 31,000 children and pregnant women. In less than two years, Common Health’s platform has been used to provide more than 140,000 telemedicine consultations and to deliver more than 17,000 medication orders. 

“We are excited to launch this service as a first step in helping families across Southeast Asia save money and achieve better health outcomes,” said Guilford. “We look forward to incorporating new offerings like diagnostics and insurance to make Common Health the first port of call for people with diabetes, hypertension, and other chronic health needs.”

About Common Health

Common Health, Inc. is a purpose-driven company that helps families in Southeast Asia manage complex health needs like chronic diseases, pregnancy, and early childhood care. The company was founded in the United States in 2019 and started operations in Myanmar in 2021, helping healthcare providers deliver high-quality primary care and essential medications to families with children. With the launch of its new e-commerce platform, Common Health is now applying its capabilities to empower the 151 million people in Southeast Asia with diabetes and hypertension to save money and achieve better health. For more information, visit www.commonhealth.com.mm.

Contact Information:

Nang Nwe

Commercial Manager, Common Health

[email protected]

+95 9765 442 738

Original Source:

Common Health Launches Southeast Asia’s First E-Commerce Platform for Chronic Diseases

Editor
March 20, 2023

San Diego-Based Shoreline Recovery Center Addresses the Opioid Epidemic Among Young Adult Males With Education, Treatment and Comprehensive Programming

SAN DIEGO, March 18, 2023 (Newswire.com)
–
Shoreline Recovery Center is addressing the opioid crisis through a process that involves giving patients med…

Editor
March 18, 2023

ZEUS Scientific Introduces the SP30 IFA Slide Processor for dIFine as Part of the dIFine 30 System

dIFine 30 system is ZEUS Scientific’s complete solution for IFA slide processing and digital immunofluorescence imaging

ZEUS Scientific Introduces the SP30 IFA Slide Processor for dIFine as Part of the dIFine 30 System
dIFine 30 System

A complete system for IFA slide processing and digital immunofluorescence imaging – including cover slipping!


BRANCHBURG, N.J., March 17, 2023 (Newswire.com)
–
Today, ZEUS Scientific launched the dIFine 30 System, a powerful partnership pairing the ZEUS dIFine® digital immunofluorescence system with the new ZEUS SP30 slide processor. The SP30 is an easy-to-use and efficient walk-away benchtop instrument for IFA slide processing, designed to improve laboratory workflow and ensure high-quality results, including cover slipping. The SP30 can process up to 240 samples on 30 ZEUS IFA slides. With its three-probe system for fast, accurate pipetting and slide well washing, it precisely dispenses mounting media and adds coverslips, decreasing slide handling and the risk of artifacts/bubbles. The multi-drop individual well-to-well washing eliminates the risk of carryover or cross-contamination. ZEUS ANA IFA test kits feature ready-to-use reagents that can be directly loaded onto the SP30 – no pour off. Its user-friendly, intuitive software works with ZEUS dIFine, allowing for parallel processing and scanning sessions. The system connects to laboratories’ LIS to receive test requests and share the worklist with dIFine, boosting efficiency.

The FDA-cleared ZEUS dIFine System is the next generation in IFA imaging, interpretation, and pattern recognition, designed to acquire, analyze, display and store digital images of ZEUS IFA HEp-2 cells. An automated digital scanner with intelligent software, dIFine quickly delivers positive/negative results and is FDA-cleared to suggest eight common ANA HEp-2 patterns (homogenous, speckled, centromere, nucleolar, nuclear dots, nuclear membrane, cytoplasmic (ribosomal and mitochondrial)).* dIFine also instantly locates and identifies mitotic cells, assisting in pattern identification. The ability to quickly view/validate all negative samples saves users valuable time. The built-in pattern atlas can be used as a reference or training tool, allowing side-by-side comparison with ZEUS proprietary images aligned with ICAP nomenclature.

ANA HEp-2 IFA is the American College of Rheumatology (ACR) gold standard for ANA testing. A pioneer in IFA technology, ZEUS has continually delivered quality products and expertise in autoimmune serology that laboratories have relied upon since 1976.

For 45+ years, laboratories have trusted ZEUS Scientific to provide high-quality IFA ANA HEp-2 products. The ZEUS proprietary cell fixation process allows technologists to work with cells containing natural, unaltered antigens and provides clear, crisp images; excellent cell morphology; and a high number of mitotic cells, all which make pattern determination easier.

With this new launch, laboratories can take their ANA IFA testing to the next level by pairing ZEUS’s top-tier IFA ANA HEp-2 slides with the ZEUS dIFine 30 System. In addition, ZEUS is in the final phases of FDA submission for dIFine automated negative/positive determination and detection of anti-dsDNA (nDNA/Crithidia) antibodies in 2023.

For more information, please visit the ZEUS website or contact the ZEUS sales team.

* FDA 510(k) cleared. All suggested results obtained with ZEUS dIFine must be confirmed by a trained operator.

Contact Information:

Travis Smyre

Vice President Commercial

[email protected]

908-243-4911

Original Source:

ZEUS Scientific Introduces the SP30 IFA Slide Processor for dIFine as Part of the dIFine 30 System

Editor
March 17, 2023

ZEUS Scientific Introduces the SP30 IFA Slide Processor for dIFine as Part of the dIFine 30 System

dIFine 30 system is ZEUS Scientific’s complete solution for IFA slide processing and digital immunofluorescence imaging

ZEUS Scientific Introduces the SP30 IFA Slide Processor for dIFine as Part of the dIFine 30 System
dIFine 30 System

A complete system for IFA slide processing and digital immunofluorescence imaging – including cover slipping!


BRANCHBURG, N.J., March 17, 2023 (Newswire.com)
–
Today, ZEUS Scientific launched the dIFine 30 System, a powerful partnership pairing the ZEUS dIFine® digital immunofluorescence system with the new ZEUS SP30 slide processor. The SP30 is an easy-to-use and efficient walk-away benchtop instrument for IFA slide processing, designed to improve laboratory workflow and ensure high-quality results, including cover slipping. The SP30 can process up to 240 samples on 30 ZEUS IFA slides. With its three-probe system for fast, accurate pipetting and slide well washing, it precisely dispenses mounting media and adds coverslips, decreasing slide handling and the risk of artifacts/bubbles. The multi-drop individual well-to-well washing eliminates the risk of carryover or cross-contamination. ZEUS ANA IFA test kits feature ready-to-use reagents that can be directly loaded onto the SP30 – no pour off. Its user-friendly, intuitive software works with ZEUS dIFine, allowing for parallel processing and scanning sessions. The system connects to laboratories’ LIS to receive test requests and share the worklist with dIFine, boosting efficiency.

The FDA-cleared ZEUS dIFine System is the next generation in IFA imaging, interpretation, and pattern recognition, designed to acquire, analyze, display and store digital images of ZEUS IFA HEp-2 cells. An automated digital scanner with intelligent software, dIFine quickly delivers positive/negative results and is FDA-cleared to suggest eight common ANA HEp-2 patterns (homogenous, speckled, centromere, nucleolar, nuclear dots, nuclear membrane, cytoplasmic (ribosomal and mitochondrial)).* dIFine also instantly locates and identifies mitotic cells, assisting in pattern identification. The ability to quickly view/validate all negative samples saves users valuable time. The built-in pattern atlas can be used as a reference or training tool, allowing side-by-side comparison with ZEUS proprietary images aligned with ICAP nomenclature.

ANA HEp-2 IFA is the American College of Rheumatology (ACR) gold standard for ANA testing. A pioneer in IFA technology, ZEUS has continually delivered quality products and expertise in autoimmune serology that laboratories have relied upon since 1976.

For 45+ years, laboratories have trusted ZEUS Scientific to provide high-quality IFA ANA HEp-2 products. The ZEUS proprietary cell fixation process allows technologists to work with cells containing natural, unaltered antigens and provides clear, crisp images; excellent cell morphology; and a high number of mitotic cells, all which make pattern determination easier.

With this new launch, laboratories can take their ANA IFA testing to the next level by pairing ZEUS’s top-tier IFA ANA HEp-2 slides with the ZEUS dIFine 30 System. In addition, ZEUS is in the final phases of FDA submission for dIFine automated negative/positive determination and detection of anti-dsDNA (nDNA/Crithidia) antibodies in 2023.

For more information, please visit the ZEUS website or contact the ZEUS sales team.

* FDA 510(k) cleared. All suggested results obtained with ZEUS dIFine must be confirmed by a trained operator.

Contact Information:

Travis Smyre

Vice President Commercial

[email protected]

908-243-4911

Original Source:

ZEUS Scientific Introduces the SP30 IFA Slide Processor for dIFine as Part of the dIFine 30 System

Editor
March 17, 2023

Market Innovation Strategist John Singer Joins Northwind Pharmaceuticals Advisory Board

Northwind Pharmaceuticals, a rapidly growing national provider of prescription medications, chronic care programs, and pharmacy benefits, adds market innovation strategist John Singer to its strategic advisory board.
…

Editor
March 16, 2023

Introducing the All-on-4 Dental Procedure From Inspire Dental Wellness

All-On-4 dental implants offered by Inspire Dental Wellness are a popular and durable choice for full-mouth dental reconstructions.

All-On-4 implan…

Editor
March 16, 2023

Post navigation

Previous post:GRWM ΣΥΖΗΤΩΝΤΑΣ ΤΙΣ ΝΕΕΣ ΚΥΚΛΟΦΟΡΙΕΣ | BEAUTY NEWS | BEAUTYLEAKS by JuL
Next post:Cannabidiol (CBD) Market Analysis, Statistics, Revenue, Demand and Trend Analysis Research Report by 2028
US PR marketing company
VUGA Enterprises – Entertainment, marketing, and technology company
24Fashion TV - best fashion shows and social network. Free membership
24Fashion TV - best fashion shows. Free membership

Recent Posts

  • Common Health Launches Southeast Asia’s First E-Commerce Platform for Chronic Diseases March 20, 2023
  • San Diego-Based Shoreline Recovery Center Addresses the Opioid Epidemic Among Young Adult Males With Education, Treatment and Comprehensive Programming March 18, 2023
  • Impact Report: Colossal Sets New Goal After Raising Over $9.6M in 2022 March 17, 2023
  • ZEUS Scientific Introduces the SP30 IFA Slide Processor for dIFine as Part of the dIFine 30 System March 17, 2023
  • ZEUS Scientific Introduces the SP30 IFA Slide Processor for dIFine as Part of the dIFine 30 System March 17, 2023
  • 4 Questions Spouses Should Ask Each Other Before Retirement March 16, 2023
  • The Shocking Number of Gen Z’ers That Don’t Know Their Credit Score March 16, 2023
  • The Biggest Hidden Costs of Divorce in 2023 March 16, 2023
  • Millennials Are Using Credit Cards for Their Emergency Funds, Which is Not Great March 16, 2023
  • Market Innovation Strategist John Singer Joins Northwind Pharmaceuticals Advisory Board March 16, 2023
  • Sustainalytics Upgrades INNIO Group’s ESG Risk Rating From Low to Negligible Risk, Ranking INNIO Number 1 Worldwide Among Industry Peers March 16, 2023
  • Introducing the All-on-4 Dental Procedure From Inspire Dental Wellness March 16, 2023
  • Introducing the All-on-4 Dental Procedure From Inspire Dental Wellness March 16, 2023
  • Individualized Mental Health and Addiction Care Available at South Beach Detox March 16, 2023
  • ART MEDICAL Announces Partnership With Teva Israel to Bring Its Lifesaving Technology to Critical Care Units March 16, 2023
plastic surgery, stem cell clinic in kiev
Miami later and spa
  • Home
  • Lifestyle
  • Beauty & Style
  • Literature
  • Fashion
  • Health
  • Contact
Copyright © 2023 Aesthetic News | Part of VUGA Media Group | Fair Use | Terms of Use | Get Published